Lilly launches TuneLab platform to give biotechnology companies access to AI-enabled drug discovery models built through over $1 billion in research investment
1. Lilly launched TuneLab, an AI platform for drug discovery. 2. The platform leverages over $1 billion in proprietary data. 3. TuneLab aims to support early-stage biotech firms effectively. 4. Biotech partners will contribute data, enhancing mutual benefits. 5. Lilly seeks to accelerate drug development via AI innovations.